Evidence map›Paper›PMID 42907775›Full record

Observational studyBMC geriatrics2026

Vascular risk factors after stroke in the older people: a population-based study.

Maider Iza Achutegui, Federica Rizzo, Marta Olive-Gadea, Jordi Brunet, Giorgio Colangelo, Marián Muchada, Renato Simonetti, Didier Dominguez, David Cano, Marc Rodrigo-Gisbert and 9 more

Abstract readObservational Study
In one paragraph

Observational study in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Maider Iza AchuteguiHospital Universitari Vall d´Hebron. Neurology Department, Barcelona, Spain.
Federica RizzoStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Marta Olive-GadeaStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain. marta.olive@vallhebron.cat.
Jordi BrunetNora Health, Barcelona, Spain.
Giorgio ColangeloNora Health, Barcelona, Spain.
Marián MuchadaStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Renato SimonettiStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Didier DominguezAgència de Qualitat i Avaluació Sanitàries de Catalunya, PADRIS, Barcelona, Spain.
David CanoNora Health, Barcelona, Spain.
Marc Rodrigo-GisbertStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Alvaro García-TornelStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Manuel RequenaStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Noelia Rodriguez-VillatoroStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Jesus JuegaStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
David Rodríguez-LunaStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Jorge PagolaStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Marc RiboStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Carlos MolinaStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Marta RubieraStroke Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

Funding

European Commission 101057263Fundación Instituto Carlos III PI20/01768Ministerio de Asuntos Económicos y Transformación Digital MIA.2021.M02.0005
6 · The paper itself

Abstract

backgroundThe risk of recurrent stroke can be reduced by controlling modifiable risk factors such as hypertension, hypercholesterolemia, and diabetes. We aim to assess control of these key factors in a representative cohort of stroke survivors residing in Catalonia, Spain. The analysis was conducted according to the current European Stroke Organisation (ESO) guidelines, with special emphasis on an older population.

methodsAn observational, retrospective, longitudinal study was conducted using data from the population-based database of the Health Quality and Assessment Agency of Catalonia. Patients diagnosed with ischemic stroke or transient ischemic attack (TIA) between 2014 and 2019 were included. Follow-up data comprised all measurements recorded during the first year after the index event. Data were collected on blood pressure, cholesterol, and HbA1c levels, as well as on pharmacological treatment, including antithrombotic agents. A comparative analysis was performed across age groups, focusing particularly on older people (> 67 years) and very older people (> 87 years) stroke survivors. In total, 35,918 patients were included in the analysis.

resultsOf 35,918 included patients, 54% were men and the median age was 77 years (IQR 68-88); 9336 (23%) were older than 87 years. During the first year after stroke, blood pressure data were available for 63% of patients. Among them, 49% of individuals aged 18-67 years and 42% of the very older people achieved the target of < 130 mmHg. Despite blood tests with total cholesterol were available for 59%, LDL-cholesterol was specifically assessed only in 5% of patients, with 31% of the younger group and 35% of the very older people reaching the < 70 mg/dL target. Among patients with diabetes, HbA1c was assessed in 84%, and 81% of younger versus 83% of older people met the < 7% target. The prevalence of atrial fibrillation increased significantly with age; however, older people were less likely to receive oral anticoagulants (63% vs. 72-73%).

conclusionA substantial proportion of stroke survivors did not achieve the targets recommended by the ESO for secondary prevention. In the older people population, fewer patients reached optimal blood pressure control, and anticoagulant use among those with atrial fibrillation was suboptimal. Our findings highlight the need for structured post-stroke follow-up pathways, improved communication between stroke specialists and primary care physicians, and targeted interventions to optimize cardiovascular risk factor management in older people.

Indexed as

Ischemic Attack, TransientIschemic StrokePopulation SurveillanceStrokeAgedAged, 80 and overDiabetes MellitusFemaleHumansHypercholesterolemiaHypertensionLongitudinal StudiesMaleRetrospective StudiesRisk FactorsSecondary PreventionAgingGuideline complianceIschemic strokeSecondary preventionVascular risk factor

Identifiers

PMID42907775
PMCPMC13689182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.